MR-spectroscopic findings in juvenile-onset Huntington's disease

Movement Disorders

Volumn 23, Issue 13, 2008, Pages 1931-1935

  Reynolds, Norman C ^a   Prost, Robert W ^b   Mark, Leighton P ^b   Joseph, Suja A ^b  

^a CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Huntington's disease; Juvenile onset; Spectroscopy

Indexed keywords

GLUTAMIC ACID; LEVODOPA;

ADOLESCENT; ADULT; ARTICLE; ATAXIA; BEHAVIOR DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL EXAMINATION; DEMENTIA; FEMALE; HUMAN; HUNTINGTON CHOREA; JUVENILE ONSET HUNTINGTON DISEASE; MALE; MEDICAL RECORD; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; MUSCLE STIFFNESS; MYOCLONUS; NUCLEAR MAGNETIC RESONANCE SCANNER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ADOLESCENT; ASPARTIC ACID; BRAIN MAPPING; CHILD; CHILD, PRESCHOOL; CREATINE; FEMALE; GLUTAMIC ACID; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROTONS; PUTAMEN; TRINUCLEOTIDE REPEATS; YOUNG ADULT;

EID: 57049166457     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22245     Document Type: Article

References (20)

1. Nance MA, Myers RH. Juvenile onset Huntington's disease - clinical and research Perspectives. Ment Retard Dev Disabil Res Rev 2001;7:153-157.
2. Duyao MP, Ambrose CM, Myers RH, et al. Trinucleotide repeat length: instability and age of onset in Huntington's disease. Nat Genet 1993;4:387-392.
3. Myers RH, Marans K, MacDonald ME. Huntington's disease. In: Warren ST, Wells T, editors. Genetic instabilities and hereditary neurological diseases. New York: Academic Press; 1998. p 301-323.
4. Ferrante RJ, Andreassen OA, Jenkins BJ, et al. Neuroprotective effects of creatine in transgenic mouse model of Huntington's disease. J Neurosci 2000;20:4389-4397.
5. 10 and remacemide in Huntington's disease. Neurology 2001;57:397-404.
6. Kremer B, Clark CM, Almquist EW, et al. Influence of lamotrigine on progression of early Huntington's disease. Neurology 1999;53:1000-1001.
7. Huntington Study Group. Minocycline tolerability and safety in Huntington's disease. Neurology 2004;63:547-554.
8. Rosas HD, Koroshetz WJ, Jenkins BG, et al. Riluzole therapy in Huntington's disease. Mov Disord 1999;14:326-330.
9. Verhagen ML, Morris MJ, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002;59:694-699.
10. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 1998;50:1357-1365.
11. Sanchez-Pernaute R, Garcia-Segura JM, del Barrio Alba A, et al. Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology 1999;53:806-812.
12. 1H-MRS pro.les of presymptomatic and early manifest Huntington's disease. Brain Res 2005;1031:82-89.
13. Hisaoka S, Harada M, Nishitani H, Mori K. Regional magnetic resonance spectroscopy of the brain in autistic individuals. Neuroradiology 2001;43:496-498.
14. Frahm J, Michaelis T, Merboldt K-D, et al. On the N-acetyl methyl resonance in localized 1H NMR spectra of human brain in vivo. NMR Biomed 1991;4:201-204.
15. Hersch SM, Rosas HD. Neuroprotective therapy for Huntington's disease: new prospects and challenges. Expert Rev Neurotherapeutics 2001;1:111-118.
16. Schapiro M, Cecil KM, Doescher J, et al. MR imaging and spectroscopy in juvenile Huntington's disease. Pediatr Radiol 2004; 34:640-643.
17. 1H magnetic resonance spectroscopy at 0.5 Tesla. Magn Reson Med 1997;37:615-618.
18. Hinton SC, Paulsen JS, Hoffmann RG, et al. Motor timing variability increases in preclinical Huntington's disease patients as estimated onset of motor symptoms approaches. J Int Neuropsychol Soc 2007;13:539-543.
19. Langbehn DR, Paulsen JS,Huntington's Study Group. Predictors of diagnosis in Huntington's disease. Neurology 2007;68:1710-1717.
20. Aylward EH, Cordori A, Barta PE, et al. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 1996;53:1293-1296.